## Core Concept
Ondansetron is a **5-HT3 receptor antagonist** primarily used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. This mechanism is crucial for its antiemetic effects.

## Why the Correct Answer is Right
The correct answer, although not directly provided, relates to understanding the properties and uses of ondansetron. As a 5-HT3 antagonist, ondansetron effectively prevents nausea and vomiting by inhibiting the serotonin receptors in the **chemoreceptor trigger zone** of the central nervous system and in the gastrointestinal tract. This action makes it highly effective in settings like chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).

## Why Each Wrong Option is Incorrect
Given that the specific options (A, B, C, D) are not provided, let's hypothetically analyze potential incorrect statements about ondansetron:

- **Option A:** If it states ondansetron is used for treating depression, this would be incorrect because ondansetron's primary use is as an antiemetic, not as an antidepressant.
- **Option B:** If it mentions ondansetron causes significant sedation, this would be incorrect as ondansetron is known for having a favorable side effect profile with minimal sedation compared to other antiemetics.
- **Option C:** If it suggests ondansetron is ineffective against chemotherapy-induced nausea, this would be incorrect because ondansetron is indeed effective in preventing CINV.
- **Option D:** If it claims ondansetron has a high potential for addiction, this would be incorrect as ondansetron does not have a significant potential for abuse or dependence.

## Clinical Pearl / High-Yield Fact
A key point to remember is that ondansetron is particularly useful in preventing **acute** CINV and PONV. It's also noteworthy that while ondansetron and other 5-HT3 antagonists are effective against acute emesis, they may not be as effective against **delayed** emesis (occurring 24-120 hours after chemotherapy), where other agents like aprepitant may be more beneficial.

## Correct Answer: D.